Company Encyclopedia
View More
name
JW THERAP-B
02126.HK
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease.
1.377 T
02126.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking43/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-51.67%E
    • Profit Margin-347.47%E
    • Gross Margin61.23%A
  • Growth ScoreC
    • Revenue YoY2.94%C
    • Net Profit YoY1.48%C
    • Total Assets YoY-26.97%E
    • Net Assets YoY-37.55%E
  • Cash ScoreC
    • Cash Flow Margin-28.78%D
    • OCF YoY2.94%C
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreB
    • Gearing Ratio35.99%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | JW THERAP-B Oversold Seeking Bottom, Where is the Sector Rotation Window Under Pharmaceutical Divergence?

    JW THERAP-B (2126.HK) faced continued market pressure yesterday, with a short-term structure showing signs of overselling and bottom-seeking. The trading volume hit a new low for the day, with funds continuously flowing out and active buying being constrained. Technical bearish signals were significantly amplified, and fund rotation within the sector was slow, with right-side funds closely monitoring key support levels below. This week, the pharmaceutical sector as a whole is facing regulatory and policy pressures, leading to a sharp decline in market risk appetite. With frequent news on volume-based procurement, the bargaining power of innovative drug companies is once again under pressure, and pharmaceutical-themed funds are maintaining low positions, creating a strong wait-and-see atmosphere. JW THERAP-B has seen no industry positives for three days, with main funds leaning towards defensive strategies, and any intraday rebounds were quickly interrupted by selling pressure. Traders are focusing on the defensive role and the potential recovery window for sector rotation; if external sentiment warms up, a technical rebound may occur. The potential risks of short-term market fluctuations cannot be ignored, and dynamic position management and monitoring of volume signals are the main operational disciplines

    Technical Forecast·
    HK
    02126
    +1.65%
    Technical Forecast·
    HK
    02126
    +1.65%

    Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors

    Imugene Limited and JW Therapeutics have announced a strategic collaboration to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene’s onCARlytics oncolytic virus with JW Therapeutics’ Carteyva® CAR-T cell therapy. This initiative includes preclinical studies and a Phase 1 trial in China, aiming to explore new treatment paradigms for solid tumors. The collaboration seeks to generate impactful preclinical and clinical data.

    Reuters·
    HK
    02126
    +1.65%
    Reuters·
    HK
    02126
    +1.65%

    Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog

    JW THERAP-B rose over 10%, as of the time of writing, it increased by 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million. According to a report by Yicai, on November 2, it was learned that JW THERAP's CAR-T cell drug, Rukiyolunase injection, is making smooth progress in negotiations to enter the commercial health insurance innovative drug catalog, with hopes of being included in the catalog, reducing the medication burden for patients and benefiting more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection. On October 30, JW THERAP announced the signing of a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision milestone payments, option exercise fees, and milestone payments for lentiviral vector manufacturing processes

    Zhitong·
    HK
    02126
    +1.65%
    Zhitong·
    HK
    02126
    +1.65%

    The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

    On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

    Zhitong·
    HK
    02575
    +2.78%
    HK
    01228
    +2.60%
    HK
    03681
    -0.66%
    Zhitong·
    HK
    02575
    +2.78%
    HK
    01228
    +2.60%
    HK
    03681
    -0.66%

    JW THERAP-B: Has submitted Phase I study data of Rigevidon in adult patients with active systemic lupus erythematosus in China to the National Medical Products Administration

    JW THERAP-B has submitted Phase I study data of Regiokalonase in adult patients with active systemic lupus erythematosus (SLE) to the National Medical Products Administration of China. The study is a single-arm, open-label, multicenter, dose-exploration study that has enrolled 12 female patients to evaluate the safety and efficacy of Regiokalonase. The study shows that all patients have kidney involvement and still require new effective drugs after receiving various treatments

    Zhitong·
    HK
    02126
    +1.65%
    Zhitong·
    HK
    02126
    +1.65%
    © 2025 Longbridge｜Disclaimer